Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 10841 - 10848 of 12007 results

Government Shutdown Aftermath: CMS Under Pressure to Finalize Medicare Payment Rules

October 18, 2013| Alert| Viewpoint

Should we worry about Safe Harbor being suspended because of the NSA’s PRISM Program?

October 18, 2013| Blog| Viewpoint

Apocalypse Averted Again: Preliminary Thoughts on Welcoming Workers Back From the Government Shutdown

October 18, 2013| Blog| Viewpoint

End to Government Shutdown Heralds Resumption of US Immigration Processing

October 17, 2013| Alert| Viewpoint

Consent Isn’t the Only Consideration: NY Comic Con Attendees Disagree that Hijacking Twitter Accounts Makes the Event “100x cooler! For realz.”

October 17, 2013| Blog| Viewpoint

Second Circuit Court of Appeals Will Address Comcast’s Impact on Wage and Hour Class Action Lawsuits

October 17, 2013| Blog| Viewpoint

CPSC Considers Rule on Voluntary Recall Notices and Compliance Programs

October 16, 2013| Blog| Viewpoint

New York State’s Highest Court Confirms that a Request for Indefinite Leave May Constitute a Reasonable Accommodation Under the New York City Human Rights Law

October 16, 2013| Blog| Viewpoint

News & Press Releases

Mintz Advises ArriVent BioPharma on $75 Million Underwritten Public Offering

July 08, 2025

Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“

Mintz Advises S2G Investments on $40M Series B Financing of Sojo Industries

July 07, 2025

Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.

Mintz Advises Syntis Bio on $33 Million Series A Financing

July 02, 2025

Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.

View all News and Press Releases